Authors
Ellen Duong, Thomas D Wu, Charles W Tran, Conrad Foo, Karl L Banta, Lili Adams, Katherine Nutsch, Aditya A Anand, Catherine B Carbone, Alan Gutierrez, Yajun Chestnut, Camille-Charlotte Balança, William H Tomaszewski, Žaneta Andrusivová, Jian Jiang, Anthony C Antonelli, Jérémie Decalf, Jeanne Cheung, Shiuh-Ming Luoh, Sandra Rost, Lisa M McGinnis, Milena Hornburg, Eugene Y Chiang, Soyoung A Oh, Ira Mellman
Published in
Immunity. Volume 59. Issue 11. Pages 3061-3080.e8. Nov 10, 2026.
Abstract
Combination immunotherapy targeting the coinhibitory molecules TIGIT and PD-L1 promotes non-exhausted CD8+ T cell differentiation in cancer. Because anti-TIGIT efficacy requires Fc binding, we investigated the role of Fcγ receptor (FcγR)-expressing myeloid cells in the mechanism of action. Conventional dendritic cells (cDCs) were required for therapeutic efficacy. Transcriptional profiling of intratumoral myeloid cells revealed an FcγR+ cDC type-1 (cDC1)-like activation state characterized by elevated costimulatory ligands for CD28 (CD80/CD86) and CD226 (PVR) that was enriched in Fc-active anti-TIGIT combination-treated tumors. Therapy-expanded CD8+ T cells expressed CD28 and upregulated CD226 upon treatment. Mechanistically, CD28 signaling was a prerequisite for therapy-induced CD226 expression on T cells, and cDC-derived PVR promoted CD226-mediated non-exhausted T cell differentiation. Type I interferon (IFN-I), induced through FcγR engagement, maintained and amplified the FcγR+ cDC1-like state, and exogenous IFN-I rescued anti-tumor immunity upon Fc-inert anti-TIGIT and anti-PD-L1 combination. Thus, Fc-active anti-TIGIT and anti-PD-L1 therapy promotes a sequential costimulatory cascade centered on cDCs, amplified by IFN-I signaling.
PMID:
43008722
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0